New Safety Data from BerGenBio's Phase 1b Study
BerGenBio ASA, a clinical-stage biopharmaceutical company developing targeted AXL kinase inhibitors for significant medical needs, recently shared preliminary safety data from its Phase 1b BGBC016 study in patients with first-line Non-Small Cell Lung Cancer (NSCLC). This information highlights the company's commitment to finding effective treatments for challenging cancers.
Overview of the Study
The Phase 1b component of the BGBC016 study examined different escalating doses of bemcentinib, BerGenBio's selective AXL inhibitor. This trial combined bemcentinib with the standard chemo-immunotherapy regimen, which includes chemotherapy and pembrolizumab, known as Keytruda, aimed at treating advanced or metastatic NSCLC patients. The primary goal of this trial was to carefully evaluate the safety profile of this combination therapy.
Key Findings of the Phase 1b Results
The findings from the study brought forth encouraging insights:
- All three doses used in the trial displayed good tolerability, and no new safety signals emerged, supporting further development of bemcentinib for NSCLC patients.
- Bemcentinib did not show any dose-related impact on electrocardiographic changes during the observation phases, an important consideration given the known effects associated with tyrosine kinase inhibitors.
- Pharmacokinetic evaluations demonstrated that bemcentinib achieved adequate plasma exposure levels, consistent with earlier studies involving responders.
Martin Olin, CEO of BerGenBio, expressed confidence in the data, stating that it reflects a manageable safety profile for bemcentinib. He emphasized the commitment to continue the clinical trial, which is now in Phase 2a, particularly focusing on patients with mutations in the STK11 gene.
Importance of Targeting STK11 Mutations
Patients with STK11 mutations typically have a poorer response to existing treatments, making targeted therapies crucial. The AXL kinase plays a vital role in cancer survival and progression, affecting a significant percentage of NSCLC patients. Currently, up to 20% of first-line NSCLC patients may present with these mutations, highlighting the critical need for targeted interventions like bemcentinib.
Clinical Implications of Bemcentinib
The selective inhibition of AXL by bemcentinib has shown promise in preclinical models, reinforcing BerGenBio's focus on developing treatments that enhance the efficacy of immune checkpoint inhibitors. As such, the ongoing development may potentially transform the treatment landscape for patients suffering from STK11m NSCLC.
About BerGenBio ASA
Founded with a vision of transforming cancer treatment, BerGenBio is headquartered in Bergen, Norway, and operates with a subsidiary in Oxford, UK. The company is committed to advancing its lead candidate, bemcentinib, as a groundbreaking selective AXL inhibitor. Listed on the Oslo Stock Exchange under the ticker BGBIO, BerGenBio continues to engage in innovative research aimed at combating severe diseases.
Frequently Asked Questions
What is BerGenBio's main focus?
BerGenBio primarily focuses on developing innovative AXL kinase inhibitors for treating aggressive diseases, particularly cancers.
What was the main goal of the Phase 1b trial?
The Phase 1b trial aimed to assess the safety profile of bemcentinib when used in combination with standard therapies for NSCLC patients.
Why is targeting STK11 mutations important?
Targeting STK11 mutations is vital due to the poorer response these patients show to current therapies, necessitating specific treatment solutions.
What did the safety data indicate about bemcentinib?
The safety data indicated that bemcentinib has a manageable safety profile with no new safety signals, encouraging further clinical exploration.
How does BerGenBio aim to transform cancer treatment?
Through ongoing research and development of selective AXL inhibitors like bemcentinib, BerGenBio aims to enhance the effectiveness of current cancer therapies.
